Search Results - "Humar, A."

An Interventional Study Using Cell‐Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation by Kumar, D., Mian, M., Singer, L., Humar, A.

“…Cell‐mediated immune responses predict clinical cytomegalovirus (CMV) events but have not been adopted into routine practice due to lack of interventional…”
Get full text

Cytomegalovirus in Solid Organ Transplantation by Razonable, R. R., Humar, A.

Get full text

Cytomegalovirus in Solid Organ Transplant Recipients by Humar, A., Snydman, D.

Get full text

American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation by Humar, A., Michaels, M.

“…In recent years, major progress has been made in the development, investigation and clinical application of novel immunosuppressive drug therapies to prevent…”
Get full text

The Role of Antiviral Prophylaxis for the Prevention of Epstein–Barr Virus–Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review by AlDabbagh, M. A., Gitman, M. R., Kumar, D., Humar, A., Rotstein, C., Husain, S.

“…The role of antiviral prophylaxis for the prevention of posttransplant lymphoproliferative disease (PTLD) remains controversial for solid organ transplantation…”
Get full text

What's New and Hot in Clinical Organ Transplantation: Report From American Transplant Congress 2012 by Humar, A.

“…Innovative and exciting advances in the clinical sciences in organ transplantation were presented at the American Transplant Congress 2012. The full spectrum…”
Get full text

Long‐Term Medical and Psychosocial Outcomes in Living Liver Donors by Dew, M. A., Butt, Z., Humar, A., DiMartini, A. F.

“…Due to the enduring organ shortage, living donor liver transplantation has been a valuable treatment strategy for advanced liver disease patients for over 20…”
Get full text

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients by Humar, A., Lebranchu, Y., Vincenti, F., Blumberg, E. A., Punch, J. D., Limaye, A. P., Abramowicz, D., Jardine, A. G., Voulgari, A. T., Ives, J., Hauser, I. A., Peeters, P.

“…Late‐onset cytomegalovirus (CMV) disease is a significant problem with a standard 3‐month prophylaxis regimen. This multicentre, double‐blind, randomized…”
Get full text

Cell‐Mediated Immunity to Predict Cytomegalovirus Disease in High‐Risk Solid Organ Transplant Recipients by Kumar, D., Chernenko, S., Moussa, G., Cobos, I., Manuel, O., Preiksaitis, J., Venkataraman, S., Humar, A.

“…Late‐onset cytomegalovirus (CMV) disease commonly occurs after discontinuation of antiviral prophylaxis. We determined the utility of testing CD8+ T‐cell…”
Get full text

Global Transplantation COVID Report March 2020 by Ahn, C., Amer, H., Anglicheau, D., Ascher, N.L., Baan, C.C., Battsetset, G., Bat-Ireedui, B., Berney, T., Betjes, M.G.H., Bichu, S., Birn, H., Brennan, D., Bromberg, J., Caillard, S., Cannon, R.M., Cantarovich, M., Chan, A., Chen, Z.S., Chapman, J.R., Cole, E.H., Cross, N., Durand, F., Egawa, H., Emond, J.C., Farrero, M., Friend, P.J., Geissler, E.K., Ha, J., Haberal, M.A., Henderson, M.L., Hesselink, D.A., Humar, A., Jassem, W., Jeong, J.C., Kaplan, B., Kee, T., Kim, S.J., Kumar, D., Legendre, C.M., Man, K., Moulin, B., Muller, E., Munkhbat, R., Od-Erdene, L., Perrin, P., Rela, M., Tanabe, K., Tedesco Silva, H., Tinckam, K.T., Tullius, S.G., Wong, G.

Get full text

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients by Åsberg, A., Humar, A., Rollag, H., Jardine, A. G., Mouas, H., Pescovitz, M. D., Sgarabotto, D., Tuncer, M., Noronha, I. L., Hartmann, A.

“…Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient…”
Get full text

A Multicenter Case-control Study of the Effect of Acute Rejection and Cytomegalovirus Infection on Pneumocystis Pneumonia in Solid Organ Transplant Recipients by Hosseini-Moghaddam, S M, Shokoohi, M, Singh, G, Dufresne, S F, Boucher, A, Jevnikar, A, Prasad, G V R, Shoker, A, Kabbani, D, Hebert, M J, Cardinal, H, Houde, I, Humar, A, Kumar, D

“…Late-onset pneumocystis pneumonia (PCP) occurs beyond the first year after transplantation. PCP is associated with significant graft loss. Cytomegalovirus…”
Get full text

Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in Organ Transplant Recipients by Kumar, D., Unger, E. R., Panicker, G., Medvedev, P., Wilson, L., Humar, A.

“…Solid organ transplant recipients are at risk of morbidity from human papillomavirus (HPV)‐related diseases. Quadrivalent HPV vaccine is recommended for…”
Get full text

A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients by Natori, Y, Humar, A, Lipton, J, Kim, D D, Ashton, P, Hoschler, K, Kumar, D

“…The annual influenza vaccine is recommended for hematopoietic stem cell transplant (HSCT) patients although studies have shown suboptimal immunogenicity…”
Get full text

Impact of Immunosuppression on the Metagenomic Composition of the Intestinal Microbiome: a Systems Biology Approach to Post-Transplant Diabetes by Bhat, M., Pasini, E., Copeland, J., Angeli, M., Husain, S., Kumar, D., Renner, E., Teterina, A., Allard, J., Guttman, D. S., Humar, A.

“…Solid organ transplantation (SOT) outcomes have continued to improve, although long-term use of immunosuppressants can lead to complications such as diabetes,…”
Get full text

Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient by Khan, B., Singer, L. G., Lilly, L. B., Chaparro, C., Martinu, T., Juvet, S., Pipkin, M., Waddell, T. K., Keshavjee, S., Humar, A., Cypel, M.

“…Lung transplantation using RNA+ hepatitis C (HCV+) donors to seronegative recipients is not currently performed due to the very high risk of transmission…”
Get full text

Donor Screening for Human T‐Cell Lymphotrophic Virus 1/2: The future Is Uncertain by Humar, A.

“…Screening of organ donors for HTLV‐1/2 infection has advantages and disadvantages that must be weighed, and rational decisions will require new evidence.
See…”
Get full text

Regulatory Dendritic Cell Infusion Prolongs Kidney Allograft Survival in Nonhuman Primates by Ezzelarab, M. B., Zahorchak, A. F., Lu, L., Morelli, A. E., Chalasani, G., Demetris, A. J., Lakkis, F. G., Wijkstrom, M., Murase, N., Humar, A., Shapiro, R., Cooper, D. K. C., Thomson, A. W.

“…We examined the influence of regulatory dendritic cells (DCreg), generated from cytokine‐mobilized donor blood monocytes in vitamin D3 and IL‐10, on renal…”
Get full text

Randomized Controlled Trial of High‐Dose Intradermal Versus Standard‐Dose Intramuscular Influenza Vaccine in Organ Transplant Recipients by Baluch, A., Humar, A., Eurich, D., Egli, A., Liacini, A., Hoschler, K., Campbell, P., Berka, N., Urschel, S., Wilson, L., Kumar, D.

“…The immunogenicity of standard intramuscular (IM) influenza vaccine is suboptimal in transplant recipients. Also, recent studies suggest that alloantibody may…”
Get full text

Gastrointestinal Tract Reconstruction in Adults with Ultra-Short Bowel Syndrome: Surgical and Nutritional Outcomes by Cruz, R.J., McGurgan, J., Butera, L., Poloyac, K., Roberts, M., Stein, W., Minervini, M., Jorgensen, D.R., Humar, A.

“…Historically, adults with ultra short bowel syndrome (USBS) have been considered candidates for lifetime parenteral nutrition (PN) or are referred for visceral…”
Get full text